ConductScience.org, home

Paper36947394

The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.

Pan B and 17 others. Drugs, 2023. Cited by 32 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials. Papers, record 36947394. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36947394

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials.
PubMed
Journal
Drugs
PubMed
Year
2023
PubMed
Publication types
Systematic Review, Journal Article, Network Meta-Analysis
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
5.47
iCite
Revised in PubMed
2026-10-30
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pan BBei
2Ge LLonghttps://orcid.org/0000-0002-3555-1107
3Lai HHonghao
4Hou LLiangying
5Tian CChen
6Wang QQi
7Yang KKelu
8Lu YYao
9Zhu HHongfei
10Li MMengting
11Wang DDeren
12Li XXiuxia
13Zhang YYuqing
14Gao YYa
15Liu MMing
16Ding GGuowu
17Tian JJinhui
18Yang KKehu

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Sleep Initiation and Maintenance DisordersMajor topic
Humans
Randomized Controlled Trials as Topic
Antidepressive Agents
Sleep

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06606938FMT for Insomnia Disorder (FMT-SLEEP)Background

References159

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11,297,939A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone.N Z Med J1992https://conductscience.org/library/papers/1297939PubMed
221,120,125Sleep symptoms predict the development of the metabolic syndrome.Sleep2010https://conductscience.org/library/papers/21120125PubMed
310,674,059Meta-analysis of benzodiazepine use in the treatment of insomnia.CMAJ2000https://conductscience.org/library/papers/10674059PubMed
43,527,513Brotizolam, a triazolothienodiazepine, in insomnia.Clin Pharmacol Ther1986https://conductscience.org/library/papers/3527513PubMed
516,968,566A polysomnography study of eszopiclone in elderly patients with insomnia.Curr Med Res Opin2006https://conductscience.org/library/papers/16968566PubMed
617,702,264Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.Sleep2007https://conductscience.org/library/papers/17702264PubMed
719,584,739The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia.Int Clin Psychopharmacol2009https://conductscience.org/library/papers/19584739PubMed
831,630,016Insomnia and risk of mortality from all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies.Sleep Med Rev2019https://conductscience.org/library/papers/31630016PubMed
915,701,215Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia.Curr Med Res Opin2004https://conductscience.org/library/papers/15701215PubMed
1020,191,935Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies.J Clin Sleep Med2010https://conductscience.org/library/papers/20191935PubMed
1118,199,864Selective publication of antidepressant trials and its influence on apparent efficacy.N Engl J Med2008https://conductscience.org/library/papers/18199864PubMed
1234,902,823The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis.Sleep Med Rev2022https://conductscience.org/library/papers/34902823PubMed
1312,607,571Zolpidem "as needed" for the treatment of primary insomnia: a double-blind, placebo-controlled study.Sleep Med Rev2002https://conductscience.org/library/papers/12607571PubMed
1422,465,450A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.Sleep Med2012https://conductscience.org/library/papers/22465450PubMed
158,071,269A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.J Clin Psychiatry1994https://conductscience.org/library/papers/8071269PubMed
1616,477,959A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia.Sleep2005https://conductscience.org/library/papers/16477959PubMed
1721,966,075Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.Sleep2011https://conductscience.org/library/papers/21966075PubMed
1824,680,372Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.Lancet Neurol2014https://conductscience.org/library/papers/24680372PubMed
1911,471,853A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia.J Int Med Res2001https://conductscience.org/library/papers/11471853PubMed
2019,413,143Insomnia with objective short sleep duration is associated with a high risk for hypertension.Sleep2009https://conductscience.org/library/papers/19413143PubMed

See all 159 references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42,955,666Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.Drugs2026https://conductscience.org/library/papers/42955666PubMed
42,889,895Exploring the Molecular Mechanism of Ganoderic Acid B for Insomnia Based on Metabolomics, Network Pharmacology, Molecular Docking, and Experimental Validation.ACS Omega2026https://conductscience.org/library/papers/42889895PubMed
42,856,849Comparative effectiveness of traditional Chinese medicine treatment strategies for insomnia: a systematic review and network meta-analysis.Front Neurol2026https://conductscience.org/library/papers/42856849PubMed
42,781,607
Management of adult insomnia in Australia: a joint position statement of the Australasian Sleep Association, Sleep Health Foundation, Royal Australian College of General Practitioners, Australian Psychological Society, Pharmaceutical Society of Australia, and Australian Primary Health Care Nurses Association.
Sleep Adv2026https://conductscience.org/library/papers/42781607PubMed
42,652,956Prunella vulgaris Compound Improves Sleep Architecture and Attenuates Hippocampal Injury in Insomnia Mice.Life (Basel)2026https://conductscience.org/library/papers/42652956PubMed
42,499,498Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management.Front Pharmacol2026https://conductscience.org/library/papers/42499498PubMed
41,883,496Comparative pharmacovigilance of non-benzodiazepine receptor agonists versus dual orexin receptor antagonists for insomnia in older adults.Front Pharmacol2026https://conductscience.org/library/papers/41883496PubMed
41,483,206Pitfalls of insomnia management in the elderly: A narrative review.Neurol Sci2026https://conductscience.org/library/papers/41483206PubMed
40,434,499A new direction for adjunctive therapy of difficult-to-treat depression: examining the role of orexin receptor antagonists.Eur Arch Psychiatry Clin Neurosci2025https://conductscience.org/library/papers/40434499PubMed
40,230,824Inhalation aromatherapy for the treatment of comorbid insomnia: a systematic review and meta-analysis.Front Psychiatry2025https://conductscience.org/library/papers/40230824PubMed
40,143,154A Preliminary Report on the Effects of Daridorexant in Patients with Comorbid Insomnia and Substance Use Disorders.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/40143154PubMed
40,092,087Efficacy and safety of idiopathic normal pressure hydrocephalus shunting: a systematic review and meta-analysis.Am J Transl Res2025https://conductscience.org/library/papers/40092087PubMed
39,815,642Determinants of Dropout From a Virtual Agent-Based App for Insomnia Management in a Self-Selected Sample of Users With Insomnia Symptoms: Longitudinal Study.JMIR Ment Health2025https://conductscience.org/library/papers/39815642PubMed
39,057,556Neurexan Prescription Is Associated with Lower Risk of Sleep Disorder Recurrence and Depression Prevalence as Compared to Z-Drugs and Benzodiazepines: A Retrospective Database Analysis in Germany.Healthcare (Basel)2024https://conductscience.org/library/papers/39057556PubMed
38,776,081Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models.JAMA Netw Open2024https://conductscience.org/library/papers/38776081PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36947394

GET https://conductscience.org/api/papers/v1/36947394/references?page=2